Identification
- Summary
Iothalamic acid is a diagnostic contrast agent used in various medical imaging procedures, such as angiography, arthrography, and computed tomographic scans.
- Brand Names
- Conray, Cysto-conray, Glofil-125
- Generic Name
- Iothalamic acid
- DrugBank Accession Number
- DB09133
- Background
Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Iothalamic acid (DB09133)
- Weight
- Average: 613.916
Monoisotopic: 613.76964 - Chemical Formula
- C11H9I3N2O4
- Synonyms
- 1-deoxy-1-(methylamino)-D-glucitol 5-acetamido-2,4,6 triiodo-N-methylisophthalamate
- Iotalamic acid
- Iothalamate
- Iothalamic acid
- External IDs
- MI 216
- MI-216
- MI216
Pharmacology
- Indication
Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography. Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Diagnostic agent Renal disease •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Renal accumulation is sufficiently rapid that maximum radiographic density in the calyces and pelves occurs, in most instances, about 3 to 8 minutes after injection. In patients with impaired renal function, diagnostic opacification frequently is achieved only after prolonged periods.
- Volume of distribution
Not Available
- Protein binding
Iothalamate salts are poorly bound to serum albumin.
- Metabolism
- Not Available
- Route of elimination
Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The liver and small intestine provide the major alternate route of excretion. In patients with severe renal impairment, the excretion of this contrast medium through the gallbladder and into the small intestine sharply increases.
- Half-life
In patients with normal renal function, the alpha and beta half-lives of Conray were approximately 10 and 90 minutes, respectively.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Iothalamic acid which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- Take on an empty stomach. Do not eat the meal that occurs before the administration of iothalamic acid for examination.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Iothalamate meglumine XUW72GOP7W 13087-53-1 VLHUSFYMPUDOEL-WZTVWXICSA-N Iothalamate sodium KDN276D83N 1225-20-3 WCIMWHNSWLLELS-UHFFFAOYSA-M Iothalamate sodium I-125 31J5U3Q9ZN 17692-74-9 Not applicable Sodium Iothalamate Not Available Not Available Not applicable - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Conray Injection 600 mg/1mL Intravascular Liebel-Flarsheim Company LLC 2003-10-14 Not applicable US 
Conray 30 Solution 300 mg / mL Intravascular Liebel Flarsheim Company Llc 1992-01-29 2018-03-14 Canada 
Conray 30 Injection 300 mg/1mL Intravascular Liebel-Flarsheim Company LLC 2012-03-26 2018-09-15 US Conray 325 Solution 54.3 % Intravenous Tyco Healthcare 1979-12-31 2010-01-12 Canada Conray 400 Injection 668 mg/1mL Intravascular Mallinckrodt 1998-01-01 2009-12-31 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Vascoray Iothalamate meglumine (520 mg / mL) + Iothalamate sodium (260 mg / mL) Solution Intra-arterial; Intravenous Tyco Healthcare 1986-12-18 2010-01-12 Canada Vascoray Iothalamate meglumine (520 mg / mL) + Iothalamate sodium (260 mg / mL) Solution Intra-arterial; Intravenous Tyco Healthcare 1986-12-18 2010-01-12 Canada
Categories
- ATC Codes
- V08AA04 — Iotalamic acid
- Drug Categories
- Acids, Carbocyclic
- Alcohols
- Amino Sugars
- Benzene Derivatives
- Benzoates
- Carbohydrates
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Diagnostic Uses of Chemicals
- Drugs that are Mainly Renally Excreted
- Hexosamines
- Iodobenzoates
- Radiographic Contrast Agent
- Roentgenography
- Sugar Alcohols
- Triiodobenzoic Acids
- Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media
- X-Ray Contrast Activity
- X-Ray Contrast Media, Iodinated
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Acylaminobenzoic acid and derivatives
- Alternative Parents
- P-haloacetanilides / O-haloacetanilides / 2-halobenzoic acids / 4-halobenzoic acids / Halobenzoic acids / N-acetylarylamines / Benzoic acids / Benzamides / 1-carboxy-2-haloaromatic compounds / Benzoyl derivatives show 11 more
- Substituents
- 1-carboxy-2-haloaromatic compound / 2-halobenzoic acid / 2-halobenzoic acid or derivatives / 4-halobenzoic acid / 4-halobenzoic acid or derivatives / Acetamide / Acetanilide / Acylaminobenzoic acid or derivatives / Anilide / Aromatic homomonocyclic compound show 30 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 16CHD79MIX
- CAS number
- 2276-90-6
- InChI Key
- UXIGWFXRQKWHHA-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)
- IUPAC Name
- 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
- SMILES
- CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I
References
- General References
- Not Available
- External Links
- KEGG Drug
- D01258
- PubChem Compound
- 3737
- PubChem Substance
- 310265048
- ChemSpider
- 3606
- 1546451
- ChEBI
- 31713
- ChEMBL
- CHEMBL1201300
- ZINC
- ZINC000003830961
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Iotalamic_acid
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intravascular 600 mg/1mL Injection Intravascular 300 mg/1mL Solution Intravascular 300 mg / mL Solution Intravenous 54.3 % Injection Intravascular 668 mg/1mL Solution Intravenous 66.8 % Injection Intravascular 430 mg/1mL Solution Intravascular 430 mg / mL Solution Intravascular 600 mg / mL Liquid Urethral 430 mg / mL Injection Ureteral 172 mg/1mL Solution Urethral 172 mg / mL Injection Intravenous 1 mg/1 Injection, solution Intravenous 0.275 mCi/1mL Solution Intra-arterial; Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.123 mg/mL ALOGPS logP 2.27 ALOGPS logP 2.73 Chemaxon logS -3.7 ALOGPS pKa (Strongest Acidic) 2.13 Chemaxon pKa (Strongest Basic) -1.7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 95.5 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 102.24 m3·mol-1 Chemaxon Polarizability 38.58 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 190.14058 predictedDeepCCS 1.0 (2019) [M+H]+ 192.85417 predictedDeepCCS 1.0 (2019) [M+Na]+ 200.65804 predictedDeepCCS 1.0 (2019)
Drug created at September 29, 2015 22:06 / Updated at February 20, 2024 23:55